Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ADY1 | ISIN: SE0007789409 | Ticker-Symbol: 7XB
Frankfurt
27.06.25 | 08:07
0,012 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XBRANE BIOPHARMA AB Chart 1 Jahr
5-Tage-Chart
XBRANE BIOPHARMA AB 5-Tage-Chart

Aktuelle News zur XBRANE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.06.Onesource Specialty edges higher after inking manufacturing pact with biotech firm Xbrane2
04.06.Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia238Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane...
► Artikel lesen
XBRANE BIOPHARMA Aktie jetzt für 0€ handeln
23.05.Xbrane Biopharma AB: Xbrane Biopharma AB (publ) updates on US FDA BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS (ranibizumab)260Xbrane re-submitted the BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS® (ranibizumab) to the FDA (US Food and Drug Administration) in December 2024. After...
► Artikel lesen
08.05.Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report January-March 2025244Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report January-March 2025, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted...
► Artikel lesen
05.05.Xbrane Biopharma AB: Announcement from the annual general meeting in Xbrane Biopharma AB708The annual general meeting 2025 (the "AGM") of Xbrane Biopharma AB ("Xbrane" or the "Company") was held today on 5 May 2025 and the following resolutions were passed by the meeting. Adoption of the...
► Artikel lesen
14.04.Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB848Today on 14 April 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting. Resolution regarding approval of sale of certain...
► Artikel lesen
20.03.Alvotech Strengthens Biosimilar Portfolio With $27 Million Xbrane R&D Deal4
20.03.Alvotech Acquires Xbrane's R&D Operations in Sweden7
20.03.Alvotech acquires Xbrane's R&D operations in Sweden and biosimilar candidate XB0037
20.03.Xbrane Biopharma AB: Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million420Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees...
► Artikel lesen
20.02.Observationsstatusen för Xbrane Biopharma AB tas bort / The observation status for Xbrane Biopharma AB is removed330Den 12 augusti 2024 gavs aktierna i Xbrane Biopharma AB ("Bolaget") observationsstatus med hänvisning till osäkerhet kring Bolagets finansiella ställning. Idag, den 20 februari 2025, offentliggjorde...
► Artikel lesen
20.02.Xbrane Biopharma AB: Xbrane Biopharma releases Year-end Report 2024329Xbrane Biopharma AB's (publ.) ("Xbrane") Year-end Report 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEW FOURTH QUARTER 2024* • Revenue amounted to SEK 65.8...
► Artikel lesen
09.01.Xbrane Biopharma AB: Xbrane Biopharma appoints Jane Benyamin as acting Chief Financial Officer394Xbrane announces today that it has appointed Jane Benyamin as acting CFO as of January 9, 2025. As previously announced, the company's current CFO, Anette Lindqvist, is stepping down from the role of...
► Artikel lesen
24.10.24Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-September 2024561Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-September 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWTHIRD QUARTER 2024*• Revenue...
► Artikel lesen
21.10.24Xbrane Biopharma AB: Xbrane Provides Update On The Ongoing Out-licensing Of Xdivane (nivolumab Biosimilar Candidate) And Xb003 (cimzia Biosimilar Candidate) And Its Financial Position537Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") is, as communicated on August 12th, actively seeking partners for its biosimilar candidates Xdivane and XB003. The company has reached agreement...
► Artikel lesen
27.09.24Xbrane Biopharma AB: Xbrane provides update from Scientific Advice with US FDA on Xdivane (Opdivo biosimilar candidate)1.066Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has received scientific advice from the US Food and Drug Administration (FDA) on the development of its Opdivo® biosimilar candidate Xdivane. FDA...
► Artikel lesen
28.08.24Xbrane Biopharma AB: Xbrane Biopharma releases Interim Report for January-June 2024546Xbrane Biopharma AB's (publ.) ("Xbrane") Interim Report for January-June 2024, is as of today, available on the Company's website, www.xbrane.com. FINANCIAL OVERVIEWSECOND QUARTER 2024*• Revenue amounted...
► Artikel lesen
12.08.24Nasdaq Stockholm AB: Xbrane Biopharma AB ges observationsstatus / Xbrane Biopharma AB receives observation status607Idag, den 12 augusti 2024 offentliggjorde Xbrane Biopharma AB ("Bolaget") ett pressmeddelande med information om att Bolagets rörelsekapital beräknas räcka till slutet av oktober 2024. Enligt regelverket...
► Artikel lesen
12.08.24Xbrane Biopharma AB: Xbrane provides update on the ongoing out-licensing of Xdivane (nivolumab biosimilar candidate) and XB003 (Cimzia biosimilar candidate) and its financial position555As communicated on 1 August 2024 and given the previously communicated delay in FDA approval of Ximluci® and the unforeseen termination of the license agreement with Biogen, Xbrane Biopharma AB (publ)...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1